ReviewFrontiers in pharmacology2023
Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Comparative bioavailability of three benznidazole formulations in healthy individuals: a randomised study.Memorias do Instituto Oswaldo Cruz · 2026Trial
- Synthesis and Evaluation of Peptoid-Based Compound Libraries as Inhibitors of Parasite Metallo-Aminopeptidases.ChemMedChem · 2026Article
- In Vivo Efficacy and Biochemical Target Engagement of a Chromene-Based Inhibitor of Trypanosoma cruzi Lysyl-tRNA Synthetase.Journal of medicinal chemistry · 2026Article
- Molecular modeling design of antitrypanosomal pyrazolone derivatives targeting Chagas disease: QSAR, docking, molecular dynamics and free energy calculations.Journal of molecular modeling · 2026Article
- Human Histatin 5 Exerts Anti-Trypanosomal Activity AgainstInternational journal of molecular sciences · 2026Article
- Identification of new Trypanosoma cruzi-specific protein synthesis inhibitors by using a developed high-throughput in vitro translation assay.International journal for parasitology. Drugs and drug resistance · 2026Article
- New hit compounds againstAntimicrobial agents and chemotherapy · 2026Article
- Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation.Infectious disease reports · 2026Review
- In Vivo Trypanocidal Activity of the Drug Disulfiram Combined with Benznidazole.ACS infectious diseases · 2026Article
- Mechanistic and Synergistic Evaluation of Amodiaquine-Isometamidium Combination Against Trypanosoma evansi: Integrated In Silico-In-Vitro Insights.Acta parasitologica · 2026Article
- Neglected tropical diseases: recent trends and challenges associated with its rapid diagnosis and effective therapeutic strategies.Frontiers in pharmacology · 2026Review
- Inhibitory Activity of LDT10 and LDT119, New Saturated Cardanols, AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- Temporizin-1 Meets the Membranes: Probing Membrane Inser-Tion and Disruption Mechanisms.Antibiotics (Basel, Switzerland) · 2025Article
- TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains.ACS omega · 2025Article
- Progress and Prospects of Triazoles in Advanced Therapies for Parasitic Diseases.Tropical medicine and infectious disease · 2025Review
- Repurposing Mouthwashes: Antifungal and Antibiofilm Abilities of Commercially Available Mouthwashes AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Exploring the Anti-Chagas Activity ofPlants (Basel, Switzerland) · 2025Article
- In vitro and in vivo studies on the activity and selectivity of butoconazole in experimental infection by Trypanosoma cruzi.Memorias do Instituto Oswaldo Cruz · 2025Article
- The potential of the antifungal nystatin to be repurposed to fight the protozoanFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease is a vector-borne illness caused by the protozoan parasite
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.